Several studies relate BRAF V600E with recurrence, lymph node metastasis (LNM), extrathyroidal extension, and loss of radioiodine avidity [22,23,24,25,26,27], even in the setting of micropapillary or low-risk intrathyroidal carcinoma (T1–2, N0, and M0) [28], while other studies do not independently associate tumour aggressiveness with the presence of the mutation alone, especially after the clinicopathological characteristics are considered [29,30]. This evidence concerns the gene BRAF and metastatic malignant neoplasm in the lymph nodes.